Ningbo Mishu Pharmaceutical Technology

Ningbo Mishu Pharmaceutical Technology is an innovative biotechnology company headquartered in Ningbo, China, focused on the discovery and development of small molecule therapeutics using targeted protein degradation (TPD) technologies. The company specializes in the design of molecular glues and PROTACs (Proteolysis-Targeting Chimeras) to address challenging targets in oncology and other therapeutic areas. Mishu Pharmaceutical leverages a proprietary discovery platform that combines structural biology, computational chemistry, and high-throughput screening to identify novel degraders. Their pipeline includes several pre-clinical programs aimed at treating solid tumors and hematological malignancies by degrading key disease-driving proteins. The firm is committed to advancing the field of TPD to provide transformative treatment options for patients with unmet medical needs.